IW | Epilepsy and the Periphery

Saturday, December 5, 2026 at 4:30 PM to 6:00 PM · 1 hr. 30 min. (America/Denver)
Investigators Workshop

Information

We explore emerging evidence that epilepsy can be modified through peripheral mechanisms, challenging the long-held assumption that effective therapies must directly penetrate the brain. Dr. Roopra presents data demonstrating that brief administration of the JAK inhibitor tofacitinib produces durable seizure suppression despite failure to cross the blood–brain barrier. Dr. Nicholas Varvel discusses complementary data showing that EP2 receptor antagonists confer disease modification through predominantly peripheral actions. Dr. Christophe Bernard integrates these concepts within the broader context of brain-body coupling, highlighting how peripheral signals shape epileptogenesis. Together, the workshop redefines therapeutic targets beyond the CNS.
Learning Objective 1
Consider anti-epilepsy drug action outside of the CNS
Learning Objective 2
Incorporate thinking about the peripheral immune system in epilepsy disease progression
Learning Objective 3
Integrate models of biological rhythms generated outside of the CNS in driving seizure clusters
Career Stage
Early Career (typically 0-5 years from completion of training)Mid-Career (typically 6-15 years from completion of trainingSenior (typically >15 years from completion of training)
Session ID
PERIPHERYIW26
Presentation Id
3451954
Event ID
24056
Session Type
Session